• Home
  • Victims
    • Vaccine Victims Memorial
    • Gardasil & Silgard
      • G / S Australasia
        • G / S Australia
        • G / S New Zealand
      • G / S Europe
        • G / S Czech Republic
        • G / S Denmark
        • G / S France
        • G / S Germany
        • G / S Ireland
        • G / S Italy
        • G / S Norway
        • G / S Scotland
        • G / S Spain
        • G / S United Kingdom
      • G / S N. America
        • G / S Canada
        • G / S Mexico
        • G / S United States
      • G / S S. America
        • G / S Brazil
        • G/S Colombia
    • Cervarix
      • Cervarix Asia
        • Cervarix India
        • Cervarix Philippines
      • Cervarix Europe
        • Cervarix Czech
        • Cervarix Netherlands
        • Cervarix Scotland
        • Cervarix Slovakia
        • Cervarix Spain
        • Cervarix UK
      • Cervarix N. America
        • Cervarix Mexico
  • Resources
    • HPV Testing Resources
      • Pre-HPV Vaccination
      • Post-HPV Vaccination
    • Medical Professionals
    • Vaccine Injury Attorneys
    • Political Action Groups
    • Vaccine Groups
    • Vaccine Victims Hotline
  • SANE Vax Press Releases
  • Videos
    • Vaccine Safety Videos
    • Vaccine Victim Videos
    • Pharma Videos
  • About
    • About Us
    • Who We Are
    • Press Releases
    • SANE Vax in the News
    • Contact Us

SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

  • NEWS
    • Government Agencies
      • African
      • Asian
      • Australasian
      • European
      • North American
      • South American
      • United Nations
      • WHO
    • Pharmaceutical Companies
      • CSL Biotherapies
      • GlaxoSmithKline
      • Inovio Pharmaceuticals
      • Liquidia Technologies
      • Merck & Co.
      • Novartis
      • Pfizer
      • Qiagen
      • Sanofi Aventis
      • Sanofi Pasteur MSD spmsd
      • Wyeth Laboratories
    • Science & Medicine
      • Cancer
      • Clinical Trials
      • Environmental Health
      • Heavy Metal Toxicity
      • HPV Science
      • Influenza
      • Meningitis
      • Pertussis
      • Pharmaceuticals
      • Rotavirus
      • STD’s
      • Vaccine Science
      • Women’s Health
    • Vaccine Adverse Events
    • Vaccine Injury Reporting
      • VAERS
      • VAMPSS
    • Vaccine Litigation
    • Vaccine Marketing
    • Vaccine Politics/People
    • Vaccine Victims
      • Cervarix Injuries
      • DTP/DTaP Injuries
      • Fluvax Injuries
      • Fluzone Injuries
      • Gardasil / Silgard Injuries
      • Menomune Injuries
      • MMR Injuries
      • Polio Vaccine Injuries
      • Synflorix Injuries
      • Yellow Fever Vaccine
    • Vaccines
      • Anthrax
      • Breast Cancer
      • Chicken Pox
      • Cholera
      • Combination Vaccines
      • Diphtheria
      • Hepatitis B
      • HPV
      • Influenza Vaccines
      • Malaria
      • Measles
      • Meningitis Vaccines
      • MRSA
      • Mumps
      • Norovirus
      • Pertussis Vaccines
      • Pneumococcal Disease
      • Polio
      • Rotavirus Vaccines
      • Shingles
      • Smallpox
      • TB
      • Tetanus
      • Typhoid
      • Yellow Fever Vaccine
    • Vaccines and the Media
  • WORLD NEWS
    • Africa
    • Asia
    • Australasia
    • Europe
    • North America
    • South America
  • RESEARCH
    • Cancer Research
    • Cervarix Vaccine
    • Gardasil/Silgard Vaccine
    • Human Pap. Research
    • Immunization Practices
    • Neurology
    • Vaccine Adjuvants
    • Vac. Ingredient Research
    • Vaccine Injuries
    • Vaccine Preservatives
    • Vaccine Related Research
    • Vaccine Safety
  • CITIZENS SPEAK
    • Cervical Cancer Debate
    • HPV Vax
      • Australian Concerns
      • Canadian Concerns
      • Irish Concerns
      • Spain Concerns
      • UK Concerns
      • United States Concerns
You are here: Home / NEWS . . . . . . . . / Government Agencies / Viet-American Cervical Cancer Prevention Project

Viet-American Cervical Cancer Prevention Project

February 4, 2011 By Norma Leave a Comment

It is generally accepted that persistent infection of the uterine cervix by high-risk types of the sexually acquired human papillomavirus (HPV) is necessary but not sufficient for the development of cervical cancer. Most people at some time in our lives acquire genital infections with HPV. In almost all cases, HPV infection is of no clinical significance, but genital cancers such as cervical and penile cancer can be uncommon consequences of this extremely common sexually-acquired infection. We do not fully understand why so few women develop cervical cancer, or why so few men develop penile cancer, when so many men and women are infected by HPV. Decades may elapse after initial infection with HPV and before the clinical manifestations of cancer. During this lengthy time interval, specific cellular changes occur within the cervix that may be detected by a variety of methods. These specific cellular changes are referred to as “precancerous” cervical lesions.

The development of HPV vaccines that might be useful for the prevention of cervical cancer has been a high-priority global health goal for many years. On 8 June 2006 the U.S. Food and Drug Administration (FDA) approved an HPV vaccine developed by Merck. Merck’s HPV vaccine is effective in preventing precancerous cervical lesions caused by HPV type 16 and HPV type 18 for up to 5 years following vaccination. HPV types 16 and 18 together cause about 70% of all cases of cervical cancer. HPV vaccines provide no protection against the HPV types other than 16 and 18 that, taken together, cause the remaining 30% of cervical cancers. Moreover, HPV vaccines will provide no protection for women who have already been exposed to HPV types 16 and 18 through sexual activity. For women who have already initiated sexual activity (and this group currently constitutes the great majority of the world’s women), Pap screening, rather than HPV vaccination, is the prudent option for effective cervical cancer prevention.

It may be desirable for females who can afford both HPV vaccination earlier in life (before the onset of sexual activity) and Pap screening later in life to access both of these preventive interventions. However, because all females who receive HPV vaccines must continue to be screened, and because it is uncertain whether HPV vaccines will provide any additional measurable protection for females who are also screened, the eventual added benefit of HPV vaccines for cervical cancer prevention is uncertain.

Because HPV vaccines provide no benefit to females who have already been exposed to HPV, HPV vaccines should be administered to females under the age of 13. However, the safety of HPV vaccines administered to females in this age group has not yet been adequately studied. Also, developing countries, including Vietnam, do not currently have the infrastructure to administer vaccines to young adolescents. It will therefore be necessary to choose between investing in the infrastructure to screen adult women, or investing in the infrastructure to vaccinate young adolescents. It is uncertain whether even affluent countries have the resources to invest in both screening and vaccination.

In developing countries such as Vietnam, providing access to HPV vaccination for some females will reduce access to Pap screening for others. From the population perspective of public health, this compromise is not appropriate.

Learn more…..

Related

Filed Under: Government Agencies, HPV, Vietnam Tagged With: pap screening

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Follow Us

SaneVax on FacebookSaneVax on TwitterSaneVax on LinkedInSaneVax on YoutubeSaneVax RSS Feed

Help Support SaneVax

Notice: We need your support. This massive research & presentation comes from a team of volunteers. We need your help to keep this critical information available.



SaneVax relies on support from participants like you. We are a 501 (c)(3) non-profit corporation, donations are tax deductible. Help keep this venue available and support the spirit – Thank you!

This Week’s Survivor

Celia from Madrid

Categories

Links

  • Creating an HPV Industry
  • File a VAERS Report
  • Gardasil and Unexplained Deaths
  • HPV Industry Timeline
  • HPV Mechanisms of Action in Women
  • HPV Vaccine Fact Sheet
  • Petition: Rescind HPV Vaccine Approval
  • Presentation to the FDA
  • Supreme Court Arguments

HPV Vaccine VAERS Reports

Description 12/14/2019  TOTAL
Disabled 3,092
Deaths 523
Did Not Recover 13,072
Abnormal Smear 695
Cervical Cancer 186
Infertility 52
Life-threatening 1,001
Emergency Room 15,419
Hospitalized 6,448
Extended Hosp. Stay 304
Serious 9,497
Total Adverse Events 64,270

Access expanded report here.

Related

Subscribe2


 

Log In

Featured Video

Dr. Eisenstein on childhood vaccination

Niagara Falls and Childhood Vaccination

News

SaneVax News Blog!
News

Videos

Safety • Victims • Pharma
No Genetic Epidemic

Contact

Contact S.A.N.E.Vax
S.A.N.E.VAX log thumbnail

Copyright © 2023 SaneVax, Inc. · Site by TheWebElves.com a div. of KalaRhythms.org · Log in